Feed VCYT
VC

Veracyte

VCYT · NASDAQ

$48.54 +11.18% (+$4.88)
1M -1.06%
Market Cap $3.31B
P/E Ratio 28.94x
Div. Yield -
ROE 8.64%

Bulios Fair Price

$32.03

34.0% downside

Current Price

$48.54

Undervalued Fair Value Overvalued

According to Bulios Fair Price, VCYT is currently overvalued relative to its market price. How does it work?

Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?

Piotroski F-Score Strong
7/9
Valuation
47 /100
Fair
P/B 2.39x
P/S 5.90x
P/E 28.94x
Growth
91 /100
Growing
Book val. growth 6.79%
Rev. growth 20.37%
FCF growth N/A
Profitability
91 /100
Strong
FCF margin 29.45%
Op. margin 17.03%
Gross margin 72.09%
Quality
42 /100
Average
Asset turnover 0.38x
ROA 7.70%
ROIC 7.04%
Debt
100 /100
Low
Current ratio 9.16x
Net debt/EBITDA -2.00x
Debt/Equity 0.03x
Stability
36 /100
Moderate
Profitable years 2
EPS volatility 143.88%
Beta 1.93x

Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more

Ask StockBot about VCYT
Online

About the company

Veracyte, Inc. is an American biotechnology company specializing in diagnostics and predictive testing using advanced genomic technologies. The company develops and commercializes tests for the diagnosis and monitoring of various types of cancer and other diseases, such as lung cancer, thyroid cancer, and pulmonary fibrosis. Veracyte focuses on improving diagnostic accuracy and personalizing treatment for patients through non-invasive tests that assist healthcare providers in selecting the most appropriate therapeutic approach.

Sector

Healthcare

Industry

Medical - Diagnostics & Research

CEO

Marc Stapley

Employees

755

Headquarters

South San Francisco

Upcoming events

03 NOV

Earnings

Upcoming earnings report

39d

We use essential cookies to run the website and optional analytics cookies to measure usage. See our Privacy Policy.